News

Filter

Current filters:

USAGW Pharmaceuticals

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

22-10-2014

Cannabinoid product specialist GW Pharmaceuticals has been granted orphan designation by the European…

CNS DiseasesepidiolexGW PharmaceuticalsPharmaceuticalResearchUSA

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

06-06-2014

The US Food and Drug Administration has granted Fast Track designation to UK-based GW Pharmaceuticals’…

epidiolexGW PharmaceuticalsPharmaceuticalRare diseasesRegulationTreatment of Dravet syndromeUSA

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

04-06-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

epidiolexGW PharmaceuticalsMedication-resistant epilepsyNeurologicalPharmaceuticalResearchUSA

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

07-05-2014

UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created…

BoardroomGW PharmaceuticalsPharmaceuticalUKUSA

US orphan status for GW Pharma’s Epidiolex in Lennox-Gastaut syndrome

28-02-2014

UK-based GW Pharmaceuticals says that the Food and Drug Administration has granted orphan drug designation…

epidiolexGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationUSA

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

15-11-2013

GW Pharmaceuticals (Nasdaq: GWPH) has been granted orphan drug designation by the US Food and Drug Administration…

EuropeGW PharmaceuticalsNorth AmericaPharmaceuticalRare diseasesRegulationUKUSA

COMPANY SPOTLIGHT

Menarini

Back to top